Imperial Innovations led the round, while Consort Medical also participated as it enters into a collaboration agreement with the retinal disease treatment developer.
Precision Ocular, a UK-based retinal disease treatment provider, has raised £13.5m ($19m) in a round led by Imperial Innovations, the investment firm set up by Imperial College London.
Imperial Innovations provided £6.9m in return for a 28.5% stake, while contract drug development and manufacturing company Consort Medical committed £3.3m. The remainder has been provided by drug encapsulation company Hovione Scientia and VC firm NeoMed.
Imperial Innovations acts as the tech transfer office of Imperial College and several NHS Trusts linked…
